OMNITROPE

Reason for request

Clinical Benefit

Moderate	Children Growth retardation in children born small for their gestational age : The actual benefit of OMNITROPE for this indication is moderate. Growth retardation associated with Prader-Willi Syndrome : The actual benefit of this medicinal product is moderate. Adults The actual benefit of this medicinal product is moderate.
Substantial	Children Growth retardation associated with somatotropic deficiency : The actual benefit of this medicine is substantial. Growth retardation associated with Turner Syndrome : The actual benefit of this medicine is substantial. Growth retardation associated with chronic renal insufficiency : The actual benefit of this proprietary drug is substantial.

Clinical Added Value

no clinical added value

OMNITROPE does not improve the actual benefit in comparison with GENOTONORM (IABV).